Novo Nordisk, the Danish pharmaceutical giant behind the blockbuster weight-loss drugs Ozempic and Wegovy, is facing increasing scrutiny despite surging profits. While demand for its obesity treatments continues to climb, the company is navigating challenges including regulatory reviews of its advertising practices in Ireland and a scrapped mega-factory project in Dublin.
The Irish advertising regulator and medicines regulators are examining Novo Nordisk’s promotional activities in Ireland, according to reports. The company has focused its advertising on raising awareness of obesity as a disease, deliberately avoiding the naming of specific prescription drugs like Ozempic and Wegovy, a tactic designed to circumvent rules prohibiting direct-to-consumer advertising of prescription medications.
Novo Nordisk’s financial success is underscored by significant payments made to healthcare professionals in Ireland. Last year, the company disbursed €446,000 in fees and expenses to over 300 doctors, nurses, academics, and other healthcare staff for sponsored talks, consultancy work, and travel. An additional €250,000 was provided to universities, hospitals, and other organizations in the form of grants, and donations. These payments, disclosed by the Irish Pharmaceutical Healthcare Association (Ipha), coincide with the growing popularity of Ozempic and Wegovy.
The company’s expansion in Ireland has been notable, with its workforce more than doubling in recent years to over 50 staff. However, a planned substantial investment in a new manufacturing facility in Dublin was unexpectedly cancelled, raising questions about the company’s long-term commitment to the country. Nina Hovland, head of Irish operations for Novo Nordisk, has acknowledged the decision to scrap the factory but outlined continued plans for the company’s presence in Ireland.
Despite concerns over potential US tariffs, Novo Nordisk continues to express confidence in its future growth. The company’s profits have soared due to the high demand for Ozempic and Wegovy, which have also gained attention through endorsements from celebrities and social media influencers. The weight loss jabs pioneered the weight loss market, but the company is now struggling to keep up with demand.
